1. Home
  2. BWLP vs DFTX Comparison

BWLP vs DFTX Comparison

Compare BWLP & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BW LPG Limited

BWLP

BW LPG Limited

HOLD

Current Price

$18.75

Market Cap

2.0B

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$17.34

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BWLP
DFTX
Founded
1935
2019
Country
Singapore
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BWLP
DFTX
Price
$18.75
$17.34
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$30.33
AVG Volume (30 Days)
278.5K
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.24%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.90
N/A
P/E Ratio
$15.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.86
$14.62
52 Week High
$18.35
$18.70

Technical Indicators

Market Signals
Indicator
BWLP
DFTX
Relative Strength Index (RSI) 76.51 51.34
Support Level $11.79 $16.31
Resistance Level N/A $18.10
Average True Range (ATR) 0.38 0.96
MACD 0.07 0.03
Stochastic Oscillator 100.00 66.52

Price Performance

Historical Comparison
BWLP
DFTX

About BWLP BW LPG Limited

BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: